Danish government will allow gradual vaccine production in Denmark

The production of coronavirus vaccines on Danish soil may happen gradually so that a future private partner will have more time to get established in Denmark, according to the background material for an upcoming market consultation.

Photo: Joachim Ladefoged/JPA

Danish Prime Minister Mette Frederiksen's wish to establish the production of covid-19 vaccines on Danish soil in collaboration with a private actor may be realized gradually.

In this way, future vaccine partners will not be forced to handle all parts of the production in Denmark on the first day, since the government will allow different stages to be initiated in Denmark at different times. For example, it may be that vaccines are only filled in Denmark to begin with, while the production of the ingredients may start up at a later point.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

In a world of options, Genmab's CEO chose partnerships

In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.

Analyst predicts slow start for Leo Pharma's Adtralza in UK

The take-up of Leo Pharma’s atopic eczema drug Adtralza in the UK will be slow-going, according to analyst bureau Global Data, after the British institute NICE released draft guidance where it was not recommend it as a standard treatment in England and Wales.

Further reading

Related articles

Latest news

See all jobs